• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Checkmate Pharmaceuticals Inc.

    5/31/22 5:21:06 PM ET
    $CMPI
    Specialty Chemicals
    Consumer Durables
    Get the next $CMPI alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39425
    Issuer: Checkmate Pharmaceuticals, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 245 Main Street
    2nd Floor
    Cambridge MASSACHUSETTS 02142
    Telephone number: (617) 682-3625
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2022-05-31 By O'Neil Blake Senior Specialist
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CMPI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMPI

    DatePrice TargetRatingAnalyst
    10/6/2021$7.00Neutral → Buy
    B of A Securities
    More analyst ratings

    $CMPI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

      CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update. "We remain focused on the execution of the clinical program for vidutolimod and are delighted with the opportunity to become part of Regeneron, who will help to accelerate the development of vidutolimod as a potential novel treatment for multiple tumor types," said Alan Bash, President and Chief Executive Officer of Checkmate. "This is an excitin

      5/12/22 4:30:00 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Checkmate Pharmaceuticals upgraded by B of A Securities with a new price target

      B of A Securities upgraded Checkmate Pharmaceuticals from Neutral to Buy and set a new price target of $7.00

      10/6/21 7:25:42 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    Leadership Updates

    Live Leadership Updates

    See more
    • Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO

      CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors. "I am very pleased to welcome Alan Bash as President and CEO. With ove

      2/9/22 8:00:00 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.

      CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors ("Board"). "Joy's impressive track record in immuno-oncology focused clinical development will be valuable as we continue to advance vidutolimod toward registration in melanoma and proof of concept in additional indications," commented Alan Fuhrman, Interim CEO and President of Checkmate. "We are pleased to welcome Joy to Checkmate's Board." Dr. Yan

      12/20/21 7:00:00 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team

      Robert F. Dolski appointed as Chief Financial Officer Katherine Eade appointed as General Counsel CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Robert F. Dolski as Chief Financial Officer. Mr. Dolski brings to Checkmate more than 20 years of diversified management experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies. In addition to Mr

      1/4/21 4:30:00 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Powell Michael

      4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

      5/31/22 10:14:50 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4 filed by Flaherty Keith T.

      4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

      5/31/22 10:12:51 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4 filed by Isacoff Oren

      4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

      5/31/22 10:11:23 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    SEC Filings

    See more
    • SEC Form 15-12B filed by Checkmate Pharmaceuticals Inc.

      15-12B - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

      6/10/22 8:37:08 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form EFFECT filed by Checkmate Pharmaceuticals Inc.

      EFFECT - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

      6/2/22 12:15:14 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form 25-NSE filed by Checkmate Pharmaceuticals Inc.

      25-NSE - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

      5/31/22 5:21:06 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Checkmate Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

      6/7/22 4:15:17 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

      6/7/22 11:39:45 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

      6/3/22 3:01:59 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables